Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Immunology
Published in: BMC Immunology 1/2014

Open Access 01-12-2014 | Research article

Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults

Authors: Thomas Poiret, Lalit Rane, Mats Remberger, Birgitta Omazic, Åsa Gustafsson-Jernberg, Nalini Kumar Vudattu, Raija Ahmed, Ingemar Ernberg, Jacek Winiarski, Isabelle Magalhaes, Olle Ringden, Markus Maeurer

Published in: BMC Immunology | Issue 1/2014

Login to get access

Abstract

Background

Interleukin 7 (IL-7) signals via the IL-7 receptor (IL-7R) and drives homeostatic T-cell proliferation in patients after allogeneic hematopoietic stem cell transplantation (aHSCT).

Purpose

We performed a prospective study in adults (n = 33) and children (n = 29) undergoing aHSCT measuring plasma IL-7 and soluble IL-7R (sIL-7R) concentrations between 1 and 12 months after HSCT in order to investigate the link between sIL-7R and clinical events after aHSCT.

Results

sIL-7R, but not IL-7, increased with time after HSCT in plasma from all patients enrolled in the study. sIL-7R values were higher at 2, 3, and 6 months (p < 0.01) if the donor was a sibling as compared to an unrelated donor. Increased sIL-7R levels were also identified in plasma from patients who were not treated with anti-thymocyte globulin (ATG). Low sIL-7R was associated with any grade of acute graft-versus-host disease (GVHD) at 2 and 6 months (p = 0.02) and with a positive CMV PCR at 2 months after HSCT (p < 0.05). Patients with cytomegalovirus (CMV) reactivation had increased IL-7 values at 2 and 3 months (p = 0.02) after HSCT. In multivariate analysis, lower sIL-7R levels were associated with acute GVHD (relative hazard (RH): 0.70, p > 0.01) and sibling donors (RH: 2.23, p = 0.004). Recipients of sibling grafts showed high levels of IL-7 (RH: 1.38, p < 0.05) and bone marrow recipients had low IL-7 levels (RH: 0.73, p = 0.04).

Conclusions

Measurement of the sIL-7R/IL-7 axis will help in guided immune monitoring after HSCT and guided interference with sIL-7R may be explored in GVHD management.
Appendix
Available only for authorised users
Literature
1.
Fry TJ, Mackall CL: Interleukin-7: from bench to clinic. Blood. 2002, 99: 3892-3904. 10.1182/blood.V99.11.3892.PubMedCrossRef
2.
Sinha ML, Fry TJ, Fowler DH, Miller G, Mackall CL: Interleukin 7 worsens graft-versus-host disease. Blood. 2002, 100: 2642-2649. 10.1182/blood-2002-04-1082.PubMedCrossRef
3.
Dean RM, Fry T, Mackall C, Steinberg SM, Hakim F, Fowler D, Odom J, Foley J, Gress R, Bishop MR: Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. J Clin Oncol. 2008, 26: 5735-5741. 10.1200/JCO.2008.17.1314.PubMedPubMedCentralCrossRef
4.
Thiant S, Labalette M, Trauet J, Coiteux V, de Berranger E, Dessaint JP, Yakoub-Agha I: Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant. 2011, 46: 1374-1381. 10.1038/bmt.2010.300.PubMedCrossRef
5.
Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, Herndier BG, Andersson J, McCune JM: Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. 2001, 7: 73-79. 10.1038/83381.PubMedCrossRef
6.
Sorg RV, McLellan AD, Hock BD, Fearnley DB, Hart DN: Human dendritic cells express functional interleukin-7. Immunobiology. 1998, 198: 514-526. 10.1016/S0171-2985(98)80075-2.PubMedCrossRef
7.
Benjamin D, Sharma V, Knobloch TJ, Armitage RJ, Dayton MA, Goodwin RG: B cell IL-7. Human B cell lines constitutively secrete IL-7 and express IL-7 receptors. J Immunol. 1994, 152: 4749-4757.PubMed
8.
Zeng M, Smith AJ, Wietgrefe SW, Southern PJ, Schacker TW, Reilly CS, Estes JD, Burton GF, Silvestri G, Lifson JD, Carlis JV, Haase AT: Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J Clin Invest. 2011, 121: 998-1008. 10.1172/JCI45157.PubMedPubMedCentralCrossRef
9.
Chung B, Barbara-Burnham L, Barsky L, Weinberg K: Radiosensitivity of thymic interleukin-7 production and thymopoiesis after bone marrow transplantation. Blood. 2001, 98: 1601-1606. 10.1182/blood.V98.5.1601.PubMedCrossRef
10.
Vudattu NK, Kuhlmann-Berenzon S, Khademi M, Seyfert V, Olsson T, Maeurer MJ: Increased numbers of IL-7 receptor molecules on CD4+CD25-CD107a+ T-cells in patients with autoimmune diseases affecting the central nervous system. PLoS One. 2009, 4: e6534-10.1371/journal.pone.0006534.PubMedPubMedCentralCrossRef
11.
Bolotin E, Smogorzewska M, Smith S, Widmer M, Weinberg K: Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood. 1996, 88: 1887-1894.PubMed
12.
Vudattu NK, Magalhaes I, Hoehn H, Pan D, Maeurer MJ: Expression analysis and functional activity of interleukin-7 splice variants. Genes Immun. 2009, 10: 132-140. 10.1038/gene.2008.90.PubMedCrossRef
13.
Alpdogan O, Schmaltz C, Muriglan SJ, Kappel BJ, Perales MA, Rotolo JA, Halm JA, Rich BE, van den Brink MR: Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood. 2001, 98: 2256-2265. 10.1182/blood.V98.7.2256.PubMedCrossRef
14.
Alpdogan O, Muriglan SJ, Eng JM, Willis LM, Greenberg AS, Kappel BJ, van den Brink MR: IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2003, 112: 1095-1107. 10.1172/JCI200317865.PubMedPubMedCentralCrossRef
15.
Chung B, Dudl EP, Min D, Barsky L, Smiley N, Weinberg KI: Prevention of graft-versus-host disease by anti IL-7Ralpha antibody. Blood. 2007, 110: 2803-2810. 10.1182/blood-2006-11-055673.PubMedPubMedCentralCrossRef
16.
Rose T, Lambotte O, Pallier C, Delfraissy JF, Colle JH: Identification and biochemical characterization of human plasma soluble IL-7R: lower concentrations in HIV-1-infected patients. J Immunol. 2009, 182: 7389-7397. 10.4049/jimmunol.0900190.PubMedCrossRef
17.
Crawley AM, Faucher S, Angel JB: Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol. 2010, 184: 4679-4687. 10.4049/jimmunol.0903758.PubMedCrossRef
18.
Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M, Oturai A, Ryder LP, Saarela J, Harbo HF, Celius EG, Salter H, Olsson T, Hillert J: Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet. 2007, 39: 1108-1113. 10.1038/ng2106.PubMedCrossRef
19.
Gregory SG, Schmidt S, Seth P, Oksenberg JR, Hart J, Prokop A, Caillier SJ, Ban M, Goris A, Barcellos LF, Lincoln R, McCauley JL, Sawcer SJ, Compston DA, Dubois B, Hauser SL, Garcia-Blanco MA, Pericak-Vance MA, Haines JL, Multiple Sclerosis Genetics Group: Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet. 2007, 39 (9): 1083-1091. 10.1038/ng2103.PubMedCrossRef
20.
Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, Hauser SL, International Multiple Sclerosis Genetics C: Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007, 357: 851-862.PubMedCrossRef
21.
Santiago JL, Alizadeh BZ, Martinez A, Espino L, de la Calle H, Fernandez-Arquero M, Figueredo MA, de la Concha EG, Roep BO, Koeleman BP, Urcelay E: Study of the association between the CAPSL-IL7R locus and type 1 diabetes. Diabetologia. 2008, 51: 1653-1658. 10.1007/s00125-008-1070-4.PubMedCrossRef
22.
O'Doherty C, Alloza I, Rooney M, Vandenbroeck K: IL7RA polymorphisms and chronic inflammatory arthropathies. Tissue Antigens. 2009, 74: 429-431. 10.1111/j.1399-0039.2009.01342.x.PubMedCrossRef
23.
Shamim Z, Ryder LP, Heilmann C, Madsen H, Lauersen H, Andersen PK, Svejgaard A, Jacobsen N, Muller K: Genetic polymorphisms in the genes encoding human interleukin-7 receptor-alpha: prognostic significance in allogeneic stem cell transplantation. Bone Marrow Transplant. 2006, 37: 485-491. 10.1038/sj.bmt.1705277.PubMedCrossRef
24.
Azarpira N, Dehghani M, Aghdaie MH, Darai M: Interleukin-7 receptor-alpha gene polymorphisms in bone marrow transplant recipients. Mol Biol Rep. 2010, 37: 27-31. 10.1007/s11033-009-9488-4.PubMedCrossRef
25.
Schaffer M, Aldener-Cannava A, Remberger M, Ringden O, Olerup O: Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation. Tissue Antigens. 2003, 62: 243-250. 10.1034/j.1399-0039.2003.00089.x.PubMedCrossRef
26.
Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L, Parkkali T, Lenhoff S, Sallerfors B, Ljungman P, Lotta Mellander, Niels Jacobsen for the Nordic Bone Marrow Transplantation Group: A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. Blood. 1994, 83: 2723-2730.PubMed
27.
Ringden O, Remberger M, Dahllof G, Garming-Legert K, Karlsson H, Svenberg P, Uhlin M, Uzunel M, Mattsson J: Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders. Eur J Haematol. 2011, 87: 503-509. 10.1111/j.1600-0609.2011.01685.x.PubMedCrossRef
28.
Remberger M, Svahn BM, Mattsson J, Ringden O: Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation. Transplantation. 2004, 78: 122-127.PubMed
29.
Ljungman P, Perez-Bercoff L, Jonsson J, Avetisyan G, Sparrelid E, Aschan J, Barkholt L, Larsson K, Winiarski J, Yun Z, Ringden O: Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006, 91: 78-83.PubMed
30.
Avetisyan G, Aschan J, Hagglund H, Ringden O, Ljungman P: Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant. 2007, 40: 865-869. 10.1038/sj.bmt.1705825.PubMedCrossRef
31.
Svahn BM, Remberger M, Myrback KE, Holmberg K, Eriksson B, Hentschke P, Aschan J, Barkholt L, Ringden O: Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Blood. 2002, 100: 4317-4324. 10.1182/blood-2002-03-0801.PubMedCrossRef
32.
Maeurer MJ, Hurd S, Martin DM, Storkus WJ, Lotze MT: Cytolytic T-cell clones define HLA-A2-restricted human cutaneous melanoma peptide epitopes: correlation with T-cell receptor usage. Cancer J Sci Am. 1995, 1: 162-170.PubMed
33.
Kreft KL, Verbraak E, Wierenga-Wolf AF, van Meurs M, Oostra BA, Laman JD, Hintzen RQ: The IL-7Ralpha pathway is quantitatively and functionally altered in CD8 T cells in multiple sclerosis. J Immunol. 2012, 188: 1874-1883. 10.4049/jimmunol.1102559.PubMedCrossRef
34.
Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M, Schlub TE, Davenport M, Crowe S, Elliott J, Hoy J, Fairley C, Stewart G, Cameron P, Lewin SR: Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation. J Infect Dis. 2010, 202: 1254-1264. 10.1086/656369.PubMedCrossRef
35.
Marks DI, Cullis JO, Ward KN, Lacey S, Syzdlo R, Hughes TP, Schwarer AP, Lutz E, Barrett AJ, Hows JM, Batchelor JR, Goldman JM: Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years. Ann Intern Med. 1993, 119: 207-214. 10.7326/0003-4819-119-3-199308010-00005.PubMedCrossRef
36.
Grundy JE, Shanley JD, Shearer GM: Augmentation of graft-versus-host reaction by cytomegalovirus infection resulting in interstitial pneumonitis. Transplantation. 1985, 39: 548-553. 10.1097/00007890-198505000-00018.PubMedCrossRef
37.
Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, Halter J, Heim D, Tichelli A, Gratwohl A, Stern M: Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010, 16: 1309-1314. 10.1016/j.bbmt.2010.03.020.PubMedCrossRef
38.
Paulin T, Ringden O, Nilsson B: Immunological recovery after bone marrow transplantation: role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow Transplant. 1987, 1: 317-328.PubMed
39.
Noel DR, Witherspoon RP, Storb R, Atkinson K, Doney K, Mickelson EM, Ochs HD, Warren RP, Weiden PL, Thomas ED: Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. Blood. 1978, 51: 1087-1105.PubMed
40.
Paulin T, Ringden O, Lonnqvist B: Faster immunological recovery after bone marrow transplantation in patients without cytomegalovirus infection. Transplantation. 1985, 39: 377-384. 10.1097/00007890-198504000-00008.PubMedCrossRef
41.
Paulin T, Ringden O, Nilsson B, Lonnqvist B, Gahrton G: Variables predicting bacterial and fungal infections after allogeneic marrow engraftment. Transplantation. 1987, 43: 393-398. 10.1097/00007890-198703000-00015.PubMedCrossRef
42.
Ringden O, Remberger M, Persson U, Ljungman P, Aldener A, Andstrom E, Aschan J, Bolme P, Dahllof G, Dalianis T, Gahrton G, Hägglund H, Lönnqvist B, Olerup O, Shanwell A, Sparrelid E, Winiarski J, Möller E, Öberg M: Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant. 1995, 15: 619-625.PubMed
43.
Dreger P, Haferlach T, Eckstein V, Jacobs S, Suttorp M, Loffler H, Muller-Ruchholtz W, Schmitz N: G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J Haematol. 1994, 87: 609-613. 10.1111/j.1365-2141.1994.tb08321.x.PubMedCrossRef
44.
Ringden O, Remberger M, Runde V, Bornhauser M, Blau IW, Basara N, Holig K, Beelen DW, Hagglund H, Basu O, Ehninger G, Fauser AA: Peripheral blood stem cell transplantation from unrelated donors: a comparison with marrow transplantation. Blood. 1999, 94: 455-464.PubMed
45.
Park JH, Yu Q, Erman B, Appelbaum JS, Montoya-Durango D, Grimes HL, Singer A: Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity. 2004, 21: 289-302. 10.1016/j.immuni.2004.07.016.PubMedCrossRef
46.
Rubinstein MP, Lind NA, Purton JF, Filippou P, Best JA, McGhee PA, Surh CD, Goldrath AW: IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response. Blood. 2008, 112: 3704-3712. 10.1182/blood-2008-06-160945.PubMedPubMedCentralCrossRef
47.
Unsinger J, McGlynn M, Kasten KR, Hoekzema AS, Watanabe E, Muenzer JT, McDonough JS, Tschoep J, Ferguson TA, McDunn JE, Morre M, Hildeman DA, Caldwell CC, Hotchkiss RS: IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol. 2010, 184: 3768-3779. 10.4049/jimmunol.0903151.PubMedPubMedCentralCrossRef
48.
Kasten KR, Prakash PS, Unsinger J, Goetzman HS, England LG, Cave CM, Seitz AP, Mazuski CN, Zhou TT, Morre M, Hotchkiss RS, Hildeman DA, Caldwell CC: Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through gamma delta T-cell IL-17 production in a murine model of sepsis. Infect Immun. 2010, 78: 4714-4722. 10.1128/IAI.00456-10.PubMedPubMedCentralCrossRef
Metadata
Title
Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults
Authors
Thomas Poiret
Lalit Rane
Mats Remberger
Birgitta Omazic
Åsa Gustafsson-Jernberg
Nalini Kumar Vudattu
Raija Ahmed
Ingemar Ernberg
Jacek Winiarski
Isabelle Magalhaes
Olle Ringden
Markus Maeurer
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Immunology / Issue 1/2014
Electronic ISSN: 1471-2172
DOI
https://doi.org/10.1186/1471-2172-15-25

Other articles of this Issue 1/2014

BMC Immunology 1/2014 Go to the issue

Research article

CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation

Research article

β2 adrenergic agonist attenuates house dust mite-induced allergic airway inflammation through dendritic cells

Research article

Exogenous interleukin-10 alleviates allergic inflammation but inhibits local interleukin-10 expression in a mouse allergic rhinitis model

Research article

Anti-cancer properties of gastropodan hemocyanins in murine model of colon carcinoma

Reviewer acknowledgement

Reviewer acknowledgement 2013

Research article

GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits